Search

Your search keyword '"Di Bisceglie, Adrian M"' showing total 1,193 results
Start Over Author "Di Bisceglie, Adrian M"
1,193 results on '"Di Bisceglie, Adrian M"'

101. Percutaneous Liver Biopsy

Author

Seeff, Leonard B., Everson, Gregory T., Morgan, Timothy R., Curto, Teresa M., Lee, William M., Ghany, Marc G., Shiffman, Mitchell L., Fontana, Robert J., Di Bisceglie, Adrian M., Bonkovsky, Herbert L., and Dienstag, Jules L.

Published
2011
Full Text
View/download PDF

102. A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC

Author

Cabrera, Roniel, primary, Singal, Amit G., additional, Colombo, Massimo, additional, Kelley, R. Kate, additional, Lee, Hannah, additional, Mospan, Andrea R., additional, Meyer, Tim, additional, Newell, Pippa, additional, Parikh, Neehar D., additional, Sangro, Bruno, additional, Reddy, K. Rajender, additional, Watkins, Stephanie, additional, Zink, Richard C., additional, and Di Bisceglie, Adrian M., additional

Published
2020
Full Text
View/download PDF

103. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

Author

Treem, William R., primary, Palmer, Melissa, additional, Lonjon-Domanec, Isabelle, additional, Seekins, Daniel, additional, Dimick-Santos, Lara, additional, Avigan, Mark I., additional, Marcinak, John F., additional, Dash, Ajit, additional, Regev, Arie, additional, Maller, Eric, additional, Patwardhan, Meenal, additional, Lewis, James H., additional, Rockey, Don C., additional, Di Bisceglie, Adrian M., additional, Freston, James W., additional, Andrade, Raul J., additional, and Chalasani, Naga, additional

Published
2020
Full Text
View/download PDF

104. Reply to: “Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)”

Author

Evon, Donna M., primary, Sarkar, Souvik, additional, Amador, Jipcy, additional, Lok, Anna S., additional, Sterling, Richard K., additional, Stewart, Paul W., additional, Reeve, Bryce B., additional, Serper, Marina, additional, Reau, Nancy, additional, Reddy, K. Rajender, additional, Di Bisceglie, Adrian M., additional, Nelson, David R., additional, Golin, Carol E., additional, Lim, Joseph K., additional, and Fried, Michael W., additional

Published
2020
Full Text
View/download PDF

125. Current and Future Systemic Therapies for Hepatocellular Carcinoma

Author

Bteich, Fernand and Di Bisceglie, Adrian M.

Subjects
Column
Abstract

Hepatocellular carcinoma (HCC) is a common cancer with unmet needs and limited effective therapeutic options. The management strategy for diagnosed HCC is based on Barcelona Clinic Liver Cancer (BCLC) staging. Advanced HCC is treated with systemic therapy comprising oral tyrosine kinase inhibitors (TKIs) and intravenous immune checkpoint inhibitors, provided that liver function is reasonable. Five new agents have been approved by the US Food and Drug Administration (FDA) in the past 2 years for the treatment of HCC: lenvatinib in the first-line setting, and regorafenib, nivolumab, pembrolizumab, and cabozantinib as second-line therapies. The FDA is considering a label expansion of ramucirumab to include its use in HCC. These therapies have all been shown to extend overall patient survival and appear to have a reasonable safety profile. Multiple ongoing trials are studying immune checkpoint inhibition alone or in combination with TKIs. The results of these trials will help determine the optimal choice, timing, and sequence of agents. This article reviews the role of currently approved systemic therapies for HCC and highlights potential future combination therapeutic strategies. The article also brings forward the concept of a developing shift to the left for therapy, as mapped out in the BCLC staging and treatment algorithm, marking earlier use of systemic therapy prior to advanced progression of the disease.

Published
2019

128. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Author

Lai, Ching-Lung, Gane, Edward, Liaw, Yun-Fan, Hsu, Chao-Wei, Thongsawat, Satawat, Wang, Yuming, Chen, Yagang, Heathcote, E. Jenny, Rasenack, Jens, Bzowej, Natalie, Naoumov, Nikolai V., Di Bisceglie, Adrian M., Zeuzem, Stefan, Moon, Young Myoung, Goodman, Zachary, Chao, George, Constance, Barbara Fielman, and Brown, Nathaniel A.

Published
2007
Full Text
View/download PDF

133. Hepatitis C virus infection in the Mothers and Infants Cohort Study

Author

Granovsky, Monica O., Minkoff, Howard L., Tess, Beatriz H., Waters, David, Hatzakis, Angelos, Devoid, David E., Landesman, Sheldon H., Rubinstein, Arye, Di Bisceglie, Adrian M., and Goedert, James J.

Subjects
Risk factors, Health aspects, HIV infections -- Health aspects -- Risk factors, Disease transmission -- Risk factors, Pediatric diseases -- Risk factors, Hepatitis -- Risk factors, Hepatitis C -- Risk factors, Pregnancy -- Health aspects, Comorbidity -- Health aspects -- Risk factors, Children -- Diseases, Hepatitis in children -- Risk factors, HIV infection -- Health aspects -- Risk factors
Abstract

ABBREVIATIONS. HCV, hepatitis C virus; HIV, human immunodeficiency virus; EIA, enzyme immunoassay; RIBA, recombinant immunoblot assay; RT-PCR, reverse transcription polymerase chain reaction; IVIG, intravenous immunoglobulin. Cloning of the hepatitis C [...]

Published
1998

134. Hepatitis C

Author

Di Bisceglie, Adrian M.

Subjects
Hepatitis C virus, Hepatitis C -- Care and treatment, Interferon alpha -- Health aspects
Published
1998

140. The treatment of chronic viral hepatitis

Author

Hoofnagle, Jay H. and Di Bisceglie, Adrian M.

Subjects
Chronic active hepatitis -- Drug therapy, Hepatitis B -- Drug therapy, Hepatitis C -- Drug therapy
Abstract

Interferon alfa remains the most useful treatment for chronic viral hepatitis, but it has considerable drawbacks. Three varieties of hepatitis can cause chronic infection and lead to chronic liver disease, cirrhosis, and liver cancer: hepatitis B (HBV), C (HCV), and D (HDV). Interferon alfa induces long-term remission in as much as 40% of HBV patients and 25% of HCV and HDV patients. Adverse effects are common and occasionally life-threatening. New virus-killing drugs such as famciclovir, lamivudine, lobucavir, adefovir dipivoxil show promise for HBV treatment, and ribavarin may prove helpful in treating HBC.

Published
1997

141. Methotrexate (MTX) Plus Ursodeoxycholic Acid (UDCA) in the Treatment of Primary Biliary Cirrhosis*#

Author

Combes, Burton, Emerson, Scott S., Flye, Nancy L., Munoz, Santiago J., Luketic, Velimir A., Mayo, Marlyn J., McCashland, Timothy M., Zetterman, Rowen K., Peters, Marion G., Di Bisceglie, Adrian M., Benner, Kent G., Kowdley, Kris V., Carithers, Robert L., Jr., Rosoff, Leonard, Jr., Garcia-Tsao, Guadalupe, Boyer, James L., Boyer, Thomas D., Martinez, Enrique J., Bass, Nathan M., Lake, John R., Barnes, David S., Bonacini, Maurizio, Lindsay, Karen L., Mills, Scott A., Markin, Rodney S., Rubin, Raphael, West, Brian A., Wheeler, Donald E., Contos, Melissa J., and Hofmann, Alan F.

Published
2005
Full Text
View/download PDF

148. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C

Author

Morishima, Chihiro, Polyak, Stephen J., Ray, Ranjit, Doherty, Michael C., Di Bisceglie, Adrian M., Malet, Peter F., Bonkovsky, Herbert L., Sullivan, Daniel G., Gretch, David R., Rothman, Alan L., Koziel, Margaret James, and Lindsay, Karen L.

Subjects
Hepatitis C virus -- Risk factors, Virus diseases -- Care and treatment, Health
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results